New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 7, 2016
20:36 EDTCELGOn The Fly: Top five weekend stock stories
Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Ford (F) plans to build a new assembly plant in Mexico and expand its existing factory near Mexico City, sharply increasing production capacity in the country as it looks to focus its U.S. efforts on trucks and SUVs, the Wall Street Journal reported. 2. GoPro (GPRO) and Microsoft (MSFT) signed a patent licensing agreement late Friday, lifting shares of the action camera maker in after-hours trading. 3. Media reports indicate Twitter (TWTR) could be rethinking its news feed, potentially ordering posts based on popularity rather than chronological date. 4. Apollo Education (APOL) received a second investigative subpoena from California's attorney general related to the marketing, recruiting, accreditation, and other aspects of its for-profit schools. 5. Celgene (CELG), Gilead (GILD), Thermo Fisher (TMO) and Vantiv (VNTV) were mentioned positively by Barron's this weekend, while Church & Dwight (CHD) was called overvalued and GoPro was identified as a possible takeover target by Under Armour (UA) or Sony (SNE).
12:38 EDTCELGCelgene, Gilead too cheap to ignore, could rise 30% in next year, Barron's says
Shares of Celgene (CELG) and Gilead (GILD) could advance 30% over the next year, Barron's contends in a feature article. Concerns over the two firms having too much revenue concentrated in just a few key products are legitimate but "solvable," and their shares now look "too cheap to ignore" amid the general rout in biotech names, the publication says. Reference Link
February 5, 2016
09:26 EDTCELGLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:04 EDTCELGCelgene resumed with a Market Perform at Leerink
Subscribe for More Information
February 4, 2016
16:37 EDTCELGCelgene reinitiated with a Market Perform at Leerink
Subscribe for More Information
10:36 EDTCELGCelgene February weekly calls activity attributed to takeover speculation
Subscribe for More Information
10:31 EDTCELGRumor: Celgene strength attributed to takeover speculation
Shares of Celgene (CELG) are moving higher amid renewed speculation Bristol-Meyers (BMY) is interested in acquiring the company.
February 3, 2016
08:57 EDTCELGPullback in biotech makes M&A more attractive, says UBS
UBS analyst Andrew Peters noted the pullback in small and mid-cap biotechs and said a consequence of the lower valuations may be an increased appetite for M&A by the larger firms. Peters noted Gilead (GILD) commented on its earnings call that "there's no question" the pullback has made M&A more attractive. UBS said with valuations so far off their highs, the question remains whether management and boards will accept deals at such depressed levels.
February 2, 2016
08:53 EDTCELGPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
January 29, 2016
08:17 EDTCELGCelgene fundamentals, valuation compelling, says Cantor
Cantor says that Celgene's sell-off was not caused by its results, but by other factors such as currency fluctuations. The firm says that the company's EPs growth remains strong, while its pipeline can enable the company to keep growing over the longer term. The firm continues to expect the company to generate strong cash flow, and it reiterates a $163 price target and Buy rating on the shares.
08:06 EDTCELGUBS said no change to bullish stance on Celgene
Subscribe for More Information
January 28, 2016
12:20 EDTCELGOn The Fly: Top stock stories at midday
Stocks on Wall Street have moved all over the place in a wild morning of trading. The averages opened sharply higher as oil prices rose above $34 a barrel. The Dow opened with triple digit gains but following reports from Iraq that it would increase oil production, and refutations of rumors that OPEC might cut production, the commodity began to weaken, taking equities with it. The averages turned negative and it looked like another rout might be in the making. Before the market fell too far, it gathered itself and moved back into positive ground and the major averages are now in the green, but not far from where they ended yesterday's session. ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 278,000 last week, versus the expected 281,000 first-time claims. Durable goods orders dropped 5.1% in December, versus expectations for a decrease of 0.7%. The core reading, which removes transportation items, was down 1.2%, versus expectations for a decline of 0.1%. The National Association of Realtors' pending home sales index for December rose 0.1%, versus expectations for it to be up 0.9%. COMPANY NEWS: Shares of Facebook (FB) surged 14.5% after the social media giant's fourth quarter earnings and revenue beat expectations. Wall Street analysts were nearly unanimous in their praise following the report, with a number increasing their price targets for its shares... Caterpillar (CAT) reported better than expected quarterly earnings, excluding certain items, but its revenue came in below the consensus forecast and the heavy equipment maker warned that it does not anticipate an improvement in the world economy or commodity prices in 2016. The stock, which had declined almost 20% in the last three months prior to this morning's report, rebounded about 2% this morning after the company jumped over its lowered profit hurdle... Shares of eBay (EBAY) and PayPal (PYPL) diverged after the recently-split companies reported their respective fourth quarter results and gave guidance, with eBay falling 13% and PayPal rising 7% near midday... The Dow Jones US Healthcare ETF (IYH) fell over 2% at midday after a number of big-names in the space gave disappointing guidance. Celgene (CELG) fell 5% following its Q4 report and fiscal year outlook, while Abbott (ABT) dropped 8% in the wake of its own results and guidance. MAJOR MOVERS: Among the notable gainers was Kinder Morgan (KMI), which rallied 8.5% after it was upgraded at Credit Suisse and Stifel. Also higher were Under Armour (UA), Dolby (DLB) and Deluxe (DLX), which gained 18%, 11% and 9%, respectively, after reporting quarterly earnings. Among the noteworthy losers was OSI Systems (OSIS), which fell 35% and was downgraded to Hold at BB&T following downbeat quarterly earnings. Also lower were Qualcomm (QCOM) and Discover (DFS), which each dropped about 7% after their quarterly earnings reports. INDEXES: Near midday, the Dow was up 1.37, or 0.01%, to 15,945.83, the Nasdaq was up 21.12, or 0.47%, to 4,489.28, and the S&P 500 was up 3.36, or 0.18%, to 1,886.31.
10:42 EDTCELGCelgene 2016 guidance looks beatable, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said Celgene reported strong Q4 growth and he believes its guidance for 2016 product sales growth and EPS both appear "achievable and surpassable", he tells investors in a post-earnings research note. The analyst, who thinks the company still has one of the highest and most sustainable 5+ year growth outlooks as well as an attractive valuation, keeps an Overweight rating and $163 price target on the stock, which is down 4% to $98 in morning trading.
08:09 EDTCELGAlliqua announces partnership with Human Longevity
Subscribe for More Information
07:36 EDTCELGCelgene sees Q1 adjusted EPS $1.27-$1.30, consensus $1.30
07:36 EDTCELGCelgene sees FY16 adjusted EPS $5.50-$5.70, consensus $5.69
Subscribe for More Information
07:31 EDTCELGCelgene reports Q4 adjusted EPS $1.18, consensus $1.22
Reports Q4 revenue $2.56B, consensus $2.54B.
January 27, 2016
14:34 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
14:29 EDTCELGCelgene technical remarks ahead of earnings news
Subscribe for More Information
12:19 EDTCELGPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use